Light therapy shows promise in tough mesothelioma trial
NCT ID NCT02662504
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study tested whether adding intrapleural photodynamic therapy (PDT) to standard surgery and chemotherapy is safe and feasible for patients with malignant pleural mesothelioma. Six participants received a light-sensitive drug followed by laser light inside the chest cavity during surgery. The goal was to see if patients could complete the full treatment without severe side effects. Results will help decide if a larger trial comparing PDT to standard care is warranted.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- porfimer sodium (Photofrin) with laser light
- What this could lead to
- If successful, this could lead to a larger trial testing whether adding photodynamic therapy to standard surgery and chemotherapy improves survival for mesothelioma patients.
- What could go wrong
- This is a very small pilot study (6 participants) focused on feasibility and safety, not effectiveness. The treatment is complex and carries risks from surgery, chemotherapy, and light sensitivity. Results may not apply to all mesothelioma types.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
6 people
The number who actually took part.
- Started
-
Jan 2016
- Finished
-
Mar 2018
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * histologically-proved epithelioid malignant pleural mesothelioma (MPM) on biopsies obtained before eP/D surgery * tumor stage: no tumor extension to controlateral lung, mediastinum, peritoneum or myocardium (\<T4); mediastinal lymph nodes extension: cN2 but no bulky N2 or N3), no metastasis (M0) * Performance status WHO PS 0-1 * patients fit to have surgery (eP/D) and chemotherapy (cisplatin-pemetrexed), based on clinical examination, complete normal biological work-up, full assessment by cardiac and pulmonary function tests. Predicted post-surgical values should be sufficient for normal daily life: FEV1\>40%; pre-surgical DLCO\>50% predicted value and VO2max \>15 ml/min/kg; (left ventricular) cardiac function \>50% and no significant pulmonary artery hypertension * written informed consent must be obtained before inclusion and randomization Exclusion Criteria: * Another histologic subtype than epithelioid MPM at the time of diagnosis * Bulky N2, N3 and/or M1 stage (UICC/IMIG 1995) * prior chemotherapy for mesothelioma * prior radiotherapy of thorax, neck or upper abdomen * other malignancy treated within 5 years, except basal cell carcinoma or in situ carcinoma of the cervix * contra-indication for MPM surgery or chemotherapy (cisplatin and pemetrexed): cardiac failure, pulmonary hypertension, liver or kidney dysfunction (GFR\<60 ml/min), uncontrolled infection, previous major neurotoxicity or ototoxicity,... or other severe condition according to the investigator * pregnancy or breast feeding * contra-indication for porfimer sodium (Photofrin): porphyria or known hypersensitivity to porphyrins, severe hepatic impairment, tracheo-oesophageal or broncho-oesophageal fistula, suspected erosion of major blood vessels due to risk of massive, potentially fatal haemorrhage * A previous talc pleurodesis during diagnostic thoracoscopy is NOT an exclusion criteria but talc on mediastinal pleura should be avoided to not keep away from eP/D.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Epithelioid malignant pleural mesothelioma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHRU de Lille Hôpital Calmette
Lille, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Chest-Injected drug drain Cancer's fluid trap?
- Can a pill that blocks multiple cancer proteins shrink Hard-to-Treat tumors?
- Triple-Drug cocktail targets Hard-to-Treat mesothelioma
- New antibody-chemo combo shows promise for mesothelioma
- Triple threat: new combo tackles rare lung cancer
- Immunotherapy before surgery shows promise for mesothelioma patients